Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz
In 2025, the immuno-oncology market in India was estimated to be around ₹3,900 crore and predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.
Dr. Reddy’s Laboratories has entered the burgeoning biosimilar immuno-oncology market in India with the launch of Nivorz, a biosimilar of Bristol Myers Squibb’s Opdivo (nivolumab). Developed and manufactured entirely within their in-house biologics facility in Bachupally, Hyderabad, the biosimilar demonstrates the company's comprehensive capabilities from development to commercialization.
In 2025, the immuno-oncology market in India was valued at around ₹3,900 crore, primarily driven by checkpoint inhibitors such as nivolumab, pembrolizumab, and toripalimab. CEO Global Generics M.V. Ramana emphasized that the launch enhances their oncology portfolio and expands their presence in the immuno-oncology space. Nivorz underwent a rigorous multi-country clinical development program involving 288 patients, including 252 from India and 36 from Russia, demonstrating comparable efficacy, safety, pharmacokinetics, and immunogenicity to the reference nivolumab.
This led to its approval by the Drugs Controller General of India (DCGI) in India. Sridevi Khambhampaty, Global Head of Biologics at Dr. Reddy’s, highlighted the significance of the launch in reinforcing their commitment to expanding patient access to high-quality immunotherapy and their focus on developing complex biosimilars. Nivorz is unique among immunotherapy agents in India, with one of the broadest ranges of approved indications, covering early-stage, locally advanced, recurrent, and metastatic diseases across solid and hematological malignancies.
Written by urgent.news from The Hindu - Sci-Tech's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
